Recent findings support that clinical responsiveness to immune checkpoint blockade (ICB) strongly relies on a combination of overall tumor mutational burden (TMB) and a pretreatment T-helper 1/interferon-γ (Th1/IFN-γ) inflammatory signature within a tumor (2–7). The gene discussed is IFNG; the disease is neoplasm.